Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,416.00+0.10%ETH$2,442.29+0.95%GOLD$4,397.70-0.05%OIL$100.86-1.03%
Smart Investors Daily
IN

NASDAQ · INAB

IN8bio, Inc.

Healthcare · Biotechnology

$1.07

Up+$0.06 (+5.94%)

Updated Sep 18, 2026, 3:07 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
8.02M
P/E ratio
-0.38
Dividend yield
0.00%
52-week range
$0.88 – $2.11
Volume
48.06K
Avg. volume
68.88K

Price performance

INAB price history

1M range · 0 trading sessions · Daily adjusted prices

INAB does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest INAB news

The latest Smart Investors Daily articles mentioning INAB.

Stock researchCompany · Overview

INAB research

Overview

Company profile and research snapshot.

Company profile

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
INAB recent ratings
DateFirmRatingTarget
Mar 13, 2026HC Wainwright & Co.Buy—
Mar 14, 2025HC Wainwright & Co.Buy—
Feb 12, 2025HC Wainwright & Co.Buy—
Feb 11, 2025Jones TradingBuy—
Nov 26, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York. Mr. Ho and members of the IN8bio management team will

Yahoo · Sep 9, 2026

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance their novel γδ T cell engager platform NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell the

Benzinga · Aug 6, 2026

IN8bio Q2 EPS $(0.25) Beats $(0.37) Estimate

IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.37) by 32.43 percent. This is a 79.84 percent increase over losses of $(1.24) per share from the same

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By